Modeling of 82 brand drugs with ≥$100 million Medicaid spend found net prices exceeded at least one international reference ...

Community response teams can adapt hospital rapid response principles for managed care organizations, targeting rising-risk members to prevent costly clinical deterioration and generate measurable ...

Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next. The biggest obstacle to translating retina’s technology ...

A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...

Analyses spanning 35,245 patients across 13 scenarios found comparable initiation of any systemic therapy in Medicare ...

INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting ...

Propensity-matched comparisons across 11 Kaiser Permanente Southern California service areas showed similar 30-day composite ...

The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...

Survivorship care and patient follow-up, being pivotal to managing treatment plans for patients with breast cancer, were key ...

Facility charges exceeded professional fees in variability for 25 of 26 services, with median facility interquartile ratios 2.56 versus 1.78 for professional prices ...

Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer ...